Product Description
Brilaroxazine (RP5063) is a new chemical entity with potent affinity and selectivity against key serotonin and dopamine receptors implicated in schizophrenia and its comorbid symptoms.
Mechanisms of Action: D2 Agonist,D3 Agonist,D4 Agonist,5-HT1A Agonist,5-HT2A Agonist
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Reviva
Company Location: CUPERTINO CA 95014
Company CEO: Laxminarayan Bhat
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: United States
Active Clinical Trial Count: 2
Highest Development Phases
Phase 3: Schizophrenia
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| RECOVER | P3 |
Recruiting |
Schizophrenia |
2025-02-01 |
|
| 2021-004193-64 | P3 |
Active, not recruiting |
Schizophrenia |
2024-06-29 |